BriaCell Therapeutics Corp.
Clinical-stage immuno-oncology company developing cellular immunotherapies for cancer.
BCTX | US
Overview
Corporate Details
- ISIN(s):
- CA10778Y3007 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
- Website:
- https://briacell.com/
Description
BriaCell Therapeutics Corp. is a clinical-stage immuno-oncology company developing a novel class of targeted cellular immunotherapies for cancer. Its lead candidate, Bria-IMT™, is a patented, off-the-shelf, cell-based therapy in a pivotal Phase 3 study for advanced metastatic breast cancer. Bria-IMT™, which has received FDA Fast Track designation, is designed to activate the patient's immune system to kill cancer cells. The company is also advancing its next-generation Bria-OTS™ platform, a personalized off-the-shelf immunotherapy that uses HLA matching to provide treatment for a broad patient population. Clinical studies for the Bria-OTS™ platform are ongoing for breast cancer, with planned expansion into prostate cancer, lung cancer, and melanoma.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all BriaCell Therapeutics Corp. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BriaCell Therapeutics Corp.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BriaCell Therapeutics Corp. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
